Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Pharmacokinetics"
DOI: 10.1007/s40262-017-0528-2
Abstract: AbstractBackgroundThe pharmacokinetics and tolerability of semaglutide, a once-weekly human glucagon-like peptide-1 analog in development for the treatment of type 2 diabetes mellitus, were investigated in subjects with/without renal impairment (RI). MethodsFifty-six subjects, categorized into renal function… read more here.
Keywords: human glucagon; semaglutide; glucagon like; pharmacokinetics tolerability ... See more keywords
Letter by Ma et al Regarding Article, "Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest: A Randomized Controlled Trial".
Sign Up to like & getrecommendations! Published in 2017 at "Circulation"
DOI: 10.1161/circulationaha.116.027072
Abstract: We read with great interest the article by Wiberg et al1 that was recently published in Circulation . The authors conducted a randomized double-blind clinical trial to demonstrate the neuroprotective effect of the glucagon-like peptide-1… read more here.
Keywords: hospital cardiac; glucagon like; peptide analog; cardiac arrest ... See more keywords